Himabindu Boja

Himabindu Boja practices at University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico.

Himabindu Boja's NPI, 1275074270, was assigned on March 10, 2017. Himabindu Boja holds New Mexico license MD2021-0642.

Himabindu Boja's primary practice is University of New Mexico Hospital, at 2211 Lomas Boulevard NE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 272-2111.

Himabindu Boja's primary practice is University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico. The medical group on file is Sound Physicians. Dmand AI also links Himabindu Boja to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Himabindu Boja practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Himabindu Boja's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Himabindu Boja is licensed in New Mexico.

CMS data shows 389 Medicare services from Himabindu Boja across 4 procedure codes in 2024, for 130 Medicare patients. Medicare paid $33,654 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 130 Medicare patients who saw Himabindu Boja in 2024. The largest group is 75 to 84, with 49 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Himabindu Boja's median patient age at 71, with 41% women.

In 2024, Himabindu Boja wrote 1,019 Medicare Part D claims for 207 patients. 90% of them were for generic drugs. CMS names the drug for 788 of them, across 27 drugs with 11 or more claims each, at $38,505 in total drug cost. In 2023, CMS named 475 claims across 21 drugs.

Himabindu Boja accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Himabindu Boja in 2023. Himabindu Boja's most frequent co-authors are James Blankenship, MD and Camila M. Maestas, MD.

CMS Open Payments shows 2 general payments to Himabindu Boja from 2 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $117.